% alzhub.org library filter
% Source: https://alzhub.org/research?author=Scheltens+P&score_min=67&about=side-effects
% 3 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{cummings2026-c800c391,
  author  = {Cummings, J. L. and Atri, A. and Scheltens, P. and others},
  title   = {{Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials}},
  journal = {The Lancet},
  year    = {2026},
  doi     = {10.1016/s0140-6736(26)00459-9},
  pmid    = {41865758},
  url     = {https://doi.org/10.1016/s0140-6736(26)00459-9}
}

@article{vandenberghe2016-27176461,
  author  = {Vandenberghe, R. and Rinne, J. O. and Boada, M. and Katayama, S. and Scheltens, P. and Vellas, B. and Tuchman, M. and Gass, A. and others},
  title   = {{Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials}},
  journal = {Alzheimer's research \& therapy},
  year    = {2016},
  doi     = {10.1186/s13195-016-0189-7},
  pmid    = {27176461},
  url     = {https://doi.org/10.1186/s13195-016-0189-7}
}

@article{liu2018-29429971,
  author  = {Liu, E. and Wang, D. and Sperling, R. and Salloway, S. and Fox, N. C. and Blennow, K. and Scheltens, P. and Schmidt, M. E. and others},
  title   = {{Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000005060},
  pmid    = {29429971},
  url     = {https://doi.org/10.1212/wnl.0000000000005060}
}